Agreement Leads to Microsoft Healthcare’s 500+ Salesforce Selling Prevencio’s Hart Blood Tests
Prevencio, Inc. announces a Microsoft Agreement which includes Microsoft’s Azure AI-computing Cloud and Microsoft’s marketing expertise, leading to Microsoft Healthcare’s 500+ salesforce selling Prevencio’s novel AI-driven HART cardiac blood tests. Microsoft’s salesforce will sell HART tests into its existing customer base, including hospitals and life science accounts. Additional terms of the deal are not disclosed.
“We are excited to collaborate with Microsoft to launch our HART tests on the Azure AI-computing, secure cloud and to sell into large healthcare systems and Contract Research Organizations (CROs). Microsoft’s efforts will complement our corporate focus on offering our HART tests to concierge physicians”
Recently, technology companies have been in heated pursuit of integrating technology, including AI and machine learning, with healthcare. Microsoft has invested more than $500 million to assist startups in scaling commercialization. In addition to Azure AI, marketing expertise and its salesforce, Microsoft provides digital and social campaigns to promote product launch, a customized Go-to-Market plan, and targeted industry marketing and account planning.
Recommended AI News: Cryptocurrency Volatility – A Friend Or A Foe
Prevencio Principal Investigator, James L. Januzzi, MD, a practicing cardiologist at Massachusetts General Hospital (MGH) and Professor of Medicine at Harvard Medical School, said, “Heart disease is the number one cause of death in the US—killing more people than all cancers combined. With more than 15 million US heart disease patients, and tens of millions of additional patients at risk, there is a clear unmet need for highly accurate, AI-based, multi-protein blood tests. Machine learning and AI, in conjunction with multiple proteins or genes, have been successful in improving diagnosis and care of cancer patients. It is rewarding to see these important technological advancements being applied to cardiac care.”
Prevencio HART tests have consistently demonstrated higher accuracy as compared to standard risk scores or standard-of-care tests. Late this month, at the American College of Cardiology Scientific Sessions, the company will present compelling HART CAD data demonstrating high accuracy as compared to nuclear and stress echo tests. This presentation will add to the impressive 16 peer-reviewed scientific presentations and manuscripts supporting the accuracy and clinical benefit of Prevencio’s novel AI-driven HART tests.
Recommended AI News: KPMG Awarded U.S. Patent for Blockchain Application That Increases Trust in AI Data Management Practices
“We are excited to collaborate with Microsoft to launch our HART tests on the Azure AI-computing, secure cloud and to sell into large healthcare systems and Contract Research Organizations (CROs). Microsoft’s efforts will complement our corporate focus on offering our HART tests to concierge physicians,” stated Rhonda Rhyne, Prevencio’s Chief Executive Officer. “Based on robust physician and patient feedback, we plan to launch in July 2020 our HART CVE test for a patient’s one-year risk of heart attack, stroke or cardiac death and HART CAD for diagnosis of heart disease.”
Rhyne concluded, “We are grateful for our ongoing collaboration with Dr. Januzzi, MGH researchers, our lab partner Myriad RBM, and now with Microsoft. We have extensive data on our HART tests and are very pleased to transition from research use to offer our tests for patient care.”
Recommended AI News: HR Visionary Elaine Page To Lead TaxJar’s People Operations
Comments are closed, but trackbacks and pingbacks are open.